High-Dose Flu Vaccine for Seniors Affirmed by Preliminary Results
Friday, November 15, 2013

Section: Quality and Educational Programming

VNAA Southeast Regional Meeting Provides Timely Insight

VNAA has put together a terrific agenda of educational sessions for its Southeast Regional Meeting on Dec. 5-6 in High Point, N.C. Educational sessions will include how to approach a financial performance evaluation and target ways to improve, as well as a tutorial covering ICD-10 coding changes that will affect home health and hospice providers.

Learn More

Get the Only Clinical Manual Your Agency Needs.

Designed specifically to help multidisciplinary home health and hospice professional teams improve their ability to deliver high-quality and consistent care in one adaptable and comprehensive evidence-based manual, the 18th edition of VNAA's Clinical Procedure Manual is one you won't want to miss.

Order before Dec. 31, 2013 and receive an additional 15% off.

Learn More

Follow the Pathway to Best Practices

VNAA introduces a new quality improvement and workforce training resource, the VNAA Blueprint for Excellence. It is a designed to provide information and tools for home health organizations, payers, policymakers, researchers and others with a stake in improving care transitions.

Available at no cost, the VNAA Blueprint includes research- and practice-based tools and training, as well as measurement and evaluation resources to guide home health care practices.

Learn More

According to preliminary results of a large clinical trial by Sanofi Pasteur,  the company’s high-dose influenza vaccine for seniors performed significantly better against lab-confirmed flu that the traditional vaccine the Center for Infectious Disease research and Policy reports.

The trial was conducted over the past two flu seasons at 126 centers across the United States and Canada, enrolling about 32,000 seniors.  The results found that the high-dose version of Fluzone was 24.2% more effective than a standard-dose vaccine at preventing flu in adults age 65 and older. 

The high-dose Fluzone, which was approved in 2009, contains four times as much antigen as standard-dose flu vaccines.  The study also suggested that the high-dose vaccine provided better protection against pneumonia, hospitalization, and cardiorespiratory conditions. 

Read More
Post a Comment